Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients

Sharon B. Brodie, Marla J. Keller, Bruce M. Ewenstein, Paul E. Sax

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: Nephrolithiasis may be an important consequence of indinavir therapy; however little has been published on the variation in incidence between different populations of patients or the possible mechanisms of calculus formation. Objective: To examine variation in the incidence of indinavir-associated nephrolithiasis (IAN) in HIV-positive patients in relation to hemophilia and hepatitis C virus (HCV) infection. Methods: Clinical data were abstracted retrospectively from the medical records of all adult patients treated with indinavir from September 1995 to September 1997. Occurrence of first IAN, defined as flank pain and hematuria after initiation of therapy, was analyzed in relation to hemophilia status and HCV infection. Results: There were 17 episodes of IAN (22%) among 79 patients treated with indinavir. Of 10 patients with hemophilia, 50% developed IAN as compared with 17% of patients without hemophilia (P = 0.03). Median days to first IAN was 22 (range 7-110 days) for hemophiliacs and 156 (range 5-611 days) for those without hemophilia. Data for HCV status were available for 74 out of 79 patients: 10 out of 27 (37%) patients with HCV developed IAN compared with six out of 42 (14%) without HCV (P = 0.02). Conclusion: Overall incidence of IAN was higher than that previously reported and was significantly greater in hemophiliacs than in non-hemophiliacs. HCV may be a contributing factor.

Original languageEnglish (US)
Pages (from-to)2433-2437
Number of pages5
JournalAIDS
Volume12
Issue number18
StatePublished - Dec 24 1998
Externally publishedYes

Fingerprint

Indinavir
Nephrolithiasis
HIV
Hepacivirus
Incidence
Hemophilia A
Factor XI Deficiency
Virus Diseases
Flank Pain
Calculi
Hematuria
Medical Records

Keywords

  • Hemophilia
  • Hepatitis C virus
  • HIV
  • Indinavir
  • Nephrolithiasis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Brodie, S. B., Keller, M. J., Ewenstein, B. M., & Sax, P. E. (1998). Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS, 12(18), 2433-2437.

Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. / Brodie, Sharon B.; Keller, Marla J.; Ewenstein, Bruce M.; Sax, Paul E.

In: AIDS, Vol. 12, No. 18, 24.12.1998, p. 2433-2437.

Research output: Contribution to journalArticle

Brodie, SB, Keller, MJ, Ewenstein, BM & Sax, PE 1998, 'Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients', AIDS, vol. 12, no. 18, pp. 2433-2437.
Brodie, Sharon B. ; Keller, Marla J. ; Ewenstein, Bruce M. ; Sax, Paul E. / Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. In: AIDS. 1998 ; Vol. 12, No. 18. pp. 2433-2437.
@article{6e2e7ac190b84c88a581c9af615bd92d,
title = "Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients",
abstract = "Background: Nephrolithiasis may be an important consequence of indinavir therapy; however little has been published on the variation in incidence between different populations of patients or the possible mechanisms of calculus formation. Objective: To examine variation in the incidence of indinavir-associated nephrolithiasis (IAN) in HIV-positive patients in relation to hemophilia and hepatitis C virus (HCV) infection. Methods: Clinical data were abstracted retrospectively from the medical records of all adult patients treated with indinavir from September 1995 to September 1997. Occurrence of first IAN, defined as flank pain and hematuria after initiation of therapy, was analyzed in relation to hemophilia status and HCV infection. Results: There were 17 episodes of IAN (22{\%}) among 79 patients treated with indinavir. Of 10 patients with hemophilia, 50{\%} developed IAN as compared with 17{\%} of patients without hemophilia (P = 0.03). Median days to first IAN was 22 (range 7-110 days) for hemophiliacs and 156 (range 5-611 days) for those without hemophilia. Data for HCV status were available for 74 out of 79 patients: 10 out of 27 (37{\%}) patients with HCV developed IAN compared with six out of 42 (14{\%}) without HCV (P = 0.02). Conclusion: Overall incidence of IAN was higher than that previously reported and was significantly greater in hemophiliacs than in non-hemophiliacs. HCV may be a contributing factor.",
keywords = "Hemophilia, Hepatitis C virus, HIV, Indinavir, Nephrolithiasis",
author = "Brodie, {Sharon B.} and Keller, {Marla J.} and Ewenstein, {Bruce M.} and Sax, {Paul E.}",
year = "1998",
month = "12",
day = "24",
language = "English (US)",
volume = "12",
pages = "2433--2437",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "18",

}

TY - JOUR

T1 - Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients

AU - Brodie, Sharon B.

AU - Keller, Marla J.

AU - Ewenstein, Bruce M.

AU - Sax, Paul E.

PY - 1998/12/24

Y1 - 1998/12/24

N2 - Background: Nephrolithiasis may be an important consequence of indinavir therapy; however little has been published on the variation in incidence between different populations of patients or the possible mechanisms of calculus formation. Objective: To examine variation in the incidence of indinavir-associated nephrolithiasis (IAN) in HIV-positive patients in relation to hemophilia and hepatitis C virus (HCV) infection. Methods: Clinical data were abstracted retrospectively from the medical records of all adult patients treated with indinavir from September 1995 to September 1997. Occurrence of first IAN, defined as flank pain and hematuria after initiation of therapy, was analyzed in relation to hemophilia status and HCV infection. Results: There were 17 episodes of IAN (22%) among 79 patients treated with indinavir. Of 10 patients with hemophilia, 50% developed IAN as compared with 17% of patients without hemophilia (P = 0.03). Median days to first IAN was 22 (range 7-110 days) for hemophiliacs and 156 (range 5-611 days) for those without hemophilia. Data for HCV status were available for 74 out of 79 patients: 10 out of 27 (37%) patients with HCV developed IAN compared with six out of 42 (14%) without HCV (P = 0.02). Conclusion: Overall incidence of IAN was higher than that previously reported and was significantly greater in hemophiliacs than in non-hemophiliacs. HCV may be a contributing factor.

AB - Background: Nephrolithiasis may be an important consequence of indinavir therapy; however little has been published on the variation in incidence between different populations of patients or the possible mechanisms of calculus formation. Objective: To examine variation in the incidence of indinavir-associated nephrolithiasis (IAN) in HIV-positive patients in relation to hemophilia and hepatitis C virus (HCV) infection. Methods: Clinical data were abstracted retrospectively from the medical records of all adult patients treated with indinavir from September 1995 to September 1997. Occurrence of first IAN, defined as flank pain and hematuria after initiation of therapy, was analyzed in relation to hemophilia status and HCV infection. Results: There were 17 episodes of IAN (22%) among 79 patients treated with indinavir. Of 10 patients with hemophilia, 50% developed IAN as compared with 17% of patients without hemophilia (P = 0.03). Median days to first IAN was 22 (range 7-110 days) for hemophiliacs and 156 (range 5-611 days) for those without hemophilia. Data for HCV status were available for 74 out of 79 patients: 10 out of 27 (37%) patients with HCV developed IAN compared with six out of 42 (14%) without HCV (P = 0.02). Conclusion: Overall incidence of IAN was higher than that previously reported and was significantly greater in hemophiliacs than in non-hemophiliacs. HCV may be a contributing factor.

KW - Hemophilia

KW - Hepatitis C virus

KW - HIV

KW - Indinavir

KW - Nephrolithiasis

UR - http://www.scopus.com/inward/record.url?scp=0032564583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032564583&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 2433

EP - 2437

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 18

ER -